- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
AbbVie
Market Cap: US$431.3b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$254.39
7D
1.8%
1Y
32.9%
Merck
Market Cap: US$305.3b
Operates as a healthcare company worldwide.
MRK
US$127.63
7D
2.0%
1Y
56.6%
Travere Therapeutics
Market Cap: US$5.3b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$55.28
7D
-5.5%
1Y
234.8%
Sotera Health
Market Cap: US$5.2b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$18.27
7D
-0.7%
1Y
62.7%
Mesa Laboratories
Market Cap: US$523.1m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$99.44
7D
4.2%
1Y
32.4%
SIGA Technologies
Market Cap: US$255.3m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.56
7D
1.7%
1Y
-46.9%
Waters
Market Cap: US$36.8b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$378.19
7D
0.3%
1Y
27.4%
BioLife Solutions
Market Cap: US$1.4b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$30.26
7D
7.2%
1Y
41.3%